Featured Research

from universities, journals, and other organizations

Two-dose vaccine coverage necessary to reduce mumps outbreaks, research finds

Date:
May 16, 2011
Source:
Canadian Medical Association Journal
Summary:
An analysis of a recent mumps outbreak in Ontario, Canada, indicates that two doses of mumps vaccine are more effective than one and further reveals the importance of ensuring people, especially older adolescents and young adults, are up to date on their mumps vaccinations. The administration of the second dose at a later age could have an impact on outbreaks, according to a new article.

An analysis of a recent mumps outbreak in Ontario, Canada, indicates that two doses of mumps vaccine are more effective than one and further reveals the importance of ensuring people, especially older adolescents and young adults, are up to date on their mumps vaccinations. The administration of the second dose at a later age could have an impact on outbreaks, states an article in CMAJ (Canadian Medical Association Journal).

Researchers from the Ontario Agency for Health Protection and Promotion, the University of Toronto, the Ontario Ministry of Health and Long-term Care, and the North Bay Regional Health Unit in Ontario compared the effectiveness of one and two doses of the measles, mumps and rubella (MMR) vaccine observed during a mumps outbreak in Ontario between September 2009 and June 2010. Similar mumps outbreaks occurred in the United States (New York and New Jersey) and Israel at the same time, where cases were seen predominantly among males and those who had received at least one dose of the MMR vaccine.

Of 134 people in Ontario with confirmed mumps, 72% were male and 59% were between 15 and 24 years of age. Vaccination history was available for 114 (84%) people; the majority had received either no vaccine or only one dose (82 people or 72%).

The researchers found that people born between 1980 and 1994 were more likely than expected to become infected with mumps, especially those born between 1985 and 1991 (people currently aged 15 to 24).

"The clustering of cases, particularly among people born between 1985 and 1991, reflects the susceptible cohort," writes Dr. Shelley Deeks, Ontario Agency for Health Protection and Promotion, with coauthors. "In addition, the active social lifestyle of this age group may have facilitated the transmission of the disease. The predominance of male cases was likely due to the settings in which they were exposed to the virus. These settings included athletic events, such as hockey tournaments, where there is frequent close contact between people."

A review of 50 mumps outbreaks indicated the effectiveness of one dose of the MMR vaccine, which ranged from 73% to 91%, compared with the effectiveness of two doses, which ranged from 91% to 95%.

Mumps outbreaks in countries with two-dose vaccination policies are fairly unusual, although they have become more frequent since 2006. Waning immunity, a susceptible cohort of people only eligible to receive one dose of vaccine and low vaccine coverage are some of the suggestions for the resurgence of mumps in developed countries. The authors suggest that as two-dose MMR programs have been in place in Canada for about 14 years, we may start seeing the impact of waning immunity among recipients of two doses of vaccine.

"Outbreaks of mumps in Canada and abroad serve as a reminder that we cannot become complacent about vaccination programs or maximizing vaccine coverage," state the authors.

"Closely monitoring waning immunity will help to ensure that we have the necessary data for making policy decisions, such as whether a third dose of MMR vaccine is necessary or whether a different vaccine should be considered, and for evaluating the cost-effectiveness of the program," they conclude.


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Deeks, Shelley L., Lim, Gillian H., Simpson, Mary Anne, Gagne, Louise, Gubbay, Jonathan, Kristjanson, Erik, Fung, Cecilia, Crowcroft, Natasha S. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ, 2011; DOI: 10.1503/cmaj.101371

Cite This Page:

Canadian Medical Association Journal. "Two-dose vaccine coverage necessary to reduce mumps outbreaks, research finds." ScienceDaily. ScienceDaily, 16 May 2011. <www.sciencedaily.com/releases/2011/05/110516121411.htm>.
Canadian Medical Association Journal. (2011, May 16). Two-dose vaccine coverage necessary to reduce mumps outbreaks, research finds. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2011/05/110516121411.htm
Canadian Medical Association Journal. "Two-dose vaccine coverage necessary to reduce mumps outbreaks, research finds." ScienceDaily. www.sciencedaily.com/releases/2011/05/110516121411.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins